My guess is July will be SCRC's best month ever. After all, there has been five straight months of revenue increases and the opportunity for continued growth over the months to follow still exists. Keep in mind though, with just one pharmacy, the compounding revenue percent growth will eventually stabilize but even at that time the other revenue streams such as PIMD and RapiMeds will be adding significantly to the bottom line. Mr. Schneiderman has developed a little powerhouse in SCRC. Being a long term investor for over a year and a half, I couldn't be more excited about what the future will bring for SCRC. For anyone looking at SCRC, do your own DD, and I am confident you'll agree .14 is an excellent entry price. Go SCRC!!!